These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 22906921)
21. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Ahmed N; Salsman VS; Kew Y; Shaffer D; Powell S; Zhang YJ; Grossman RG; Heslop HE; Gottschalk S Clin Cancer Res; 2010 Jan; 16(2):474-85. PubMed ID: 20068073 [TBL] [Abstract][Full Text] [Related]
22. Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients. Lowenstein PR; Castro MG Clin Immunol; 2018 Apr; 189():43-51. PubMed ID: 28720549 [TBL] [Abstract][Full Text] [Related]
23. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme. Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051 [TBL] [Abstract][Full Text] [Related]
24. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. King GD; Muhammad AK; Xiong W; Kroeger KM; Puntel M; Larocque D; Palmer D; Ng P; Lowenstein PR; Castro MG J Virol; 2008 May; 82(9):4680-4. PubMed ID: 18287240 [TBL] [Abstract][Full Text] [Related]
25. Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Candolfi M; Pluhar GE; Kroeger K; Puntel M; Curtin J; Barcia C; Muhammad AK; Xiong W; Liu C; Mondkar S; Kuoy W; Kang T; McNeil EA; Freese AB; Ohlfest JR; Moore P; Palmer D; Ng P; Young JD; Lowenstein PR; Castro MG Neuro Oncol; 2007 Jul; 9(3):245-58. PubMed ID: 17522335 [TBL] [Abstract][Full Text] [Related]
26. Current status of immunotherapy and gene therapy for high-grade gliomas. Marsh JC; Goldfarb J; Shafman TD; Diaz AZ Cancer Control; 2013 Jan; 20(1):43-8. PubMed ID: 23302906 [TBL] [Abstract][Full Text] [Related]
27. Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma. VanderVeen N; Paran C; Krasinkiewicz J; Zhao L; Palmer D; Hervey-Jumper S; Ng P; Lowenstein PR; Castro MG Hum Gene Ther Clin Dev; 2013 Sep; 24(3):116-26. PubMed ID: 24007469 [TBL] [Abstract][Full Text] [Related]
28. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma. DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U Front Immunol; 2020; 11():1402. PubMed ID: 32765498 [TBL] [Abstract][Full Text] [Related]
29. Glioblastoma Immune Landscape and the Potential of New Immunotherapies. Daubon T; Hemadou A; Romero Garmendia I; Saleh M Front Immunol; 2020; 11():585616. PubMed ID: 33154756 [TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenic gene therapy in the treatment of malignant gliomas. Gatson NN; Chiocca EA; Kaur B Neurosci Lett; 2012 Oct; 527(2):62-70. PubMed ID: 22906922 [TBL] [Abstract][Full Text] [Related]
32. Stem cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Rath P; Shi H; Maruniak JA; Litofsky NS; Maria BL; Kirk MD Curr Stem Cell Res Ther; 2009 Jan; 4(1):44-9. PubMed ID: 19149629 [TBL] [Abstract][Full Text] [Related]
33. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. Juratli TA; Schackert G; Krex D Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764 [TBL] [Abstract][Full Text] [Related]
34. Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Khalsa JK; Cheng N; Keegan J; Chaudry A; Driver J; Bi WL; Lederer J; Shah K Nat Commun; 2020 Aug; 11(1):3912. PubMed ID: 32764562 [TBL] [Abstract][Full Text] [Related]
35. Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. Kamran N; Candolfi M; Baker GJ; Ayala MM; Dzaman M; Lowenstein PR; Castro MG Methods Mol Biol; 2016; 1382():467-82. PubMed ID: 26611605 [TBL] [Abstract][Full Text] [Related]
36. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy. Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290 [TBL] [Abstract][Full Text] [Related]
37. Inhibition of caveolin-1 restores myeloid cell function in human glioblastoma. Shimato S; Anderson LM; Asslaber M; Bruce JN; Canoll P; Anderson DE; Anderson RC PLoS One; 2013; 8(10):e77397. PubMed ID: 24130882 [TBL] [Abstract][Full Text] [Related]
38. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?]. Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303 [TBL] [Abstract][Full Text] [Related]